ApoE:神经疾病中的非主角演员
Lorenzo Grimaldi1,2, Eleonora Bovi1,3, Rita Formisano4
1Clinical Neurochemistry Unit and Biobank, IRCCS Santa Lucia Foundation, Via Ardeatina, 306/354, 00179 Rome, Italy.
Genes
|November 27, 2024
概括
脂蛋白E (ApoE) 影响脂质平衡,并与神经退行性疾病有关. APOE epsilon 4基因系是阿尔茨海默氏症的风险因素,预测帕金森病和脑创伤的结果会更差.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- 脂蛋白E (ApoE) 对于脂质运输和恒温至关重要.
- APOE epsilon 4 (E4) 等位基因是已知的阿尔茨海默病的风险因素.
- 新出现的证据将APOE E4与帕金森病,脑创伤和意识障碍的较差结果联系起来.
研究的目的:
- 审查ApoE在阿尔茨海默氏症以外的神经退行性疾病中的作用.
- 讨论ApoE在阿尔茨海默病,帕金森病,脑创伤和意识障碍中的临床意义.
- 简要地介绍APOE基因测试的伦理考虑.
主要方法:
- 对ApoE和神经疾病研究的文献综述.
- 分析ApoE参与疾病机制的分析,如粉样β积累和神经炎症.
- 关于APOE预测价值的临床数据的综合.
主要成果:
- ApoE E4 是一种重要的风险因素,也是各种神经系统疾病中不良结果的预测因素.
- 机制涉及复杂的相互作用,包括神经炎症和粉样β.
- 基因测试的伦理影响需要仔细考虑.
结论:
- ApoE在神经退行和神经疾病中发挥着多方面的作用.
- APOE E4 状态在多种神经疾病中具有广泛的临床影响.
- 负责任的基因测试和披露至关重要.
相关概念视频
Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Prosopagnosia
139
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
139


